Sermorelin Half-Life: About 11 to 12 Minutes

Sermorelin half-life is about 11 to 12 minutes, according to the historical Geref prescribing information. Half-life means the time it takes the body to clear half of a dose from the blood. That sounds as though the whole effect should end almost immediately. It doesn't. In a study of 30 healthy men, the peptide disappeared quickly after an intravenous dose, meaning a dose into a vein, but the growth-hormone rise lasted about three hours. The plain answer is: sermorelin stays in the bloodstream for minutes, while the hormone signal it starts can last for hours.

What the sermorelin half-life number means

Sermorelin is a peptide, or short chain of amino acids, that copies the active part of growth hormone-releasing hormone (GHRH). GHRH is the body's message to the pituitary, a small gland beneath the brain, to release growth hormone. Sermorelin sends that message; it is not growth hormone itself.

The historical Geref prescribing information reports an 11-to-12-minute half-life after either intravenous or subcutaneous administration, meaning an injection into the fatty layer under the skin. It also reports that blood levels peaked 5 to 20 minutes after a subcutaneous dose in 12 healthy volunteers. These were group averages from an older product, not a stopwatch for a current compounded prescription.

A separate human study reached a shorter figure. After a 90-minute intravenous infusion ended, the blood level of GHRH(1-29), the molecule called sermorelin, fell by half in 4.3 ± 1.4 minutes in 10 men (Soule and colleagues, The Journal of Clinical Endocrinology & Metabolism, 1994). The route, sampling, and calculation differed from the label study. The honest reading is a range measured in minutes, not one universal personal number.

As of September 9, 2026, the day this article was written, a review published June 18, 2026 in Frontiers in Endocrinology is the newest broad peer-reviewed overview of this peptide class. It reports the same 4.3 ± 1.4-minute disappearance result and describes sermorelin as short-acting. It also warns against turning a hormone response into a claim about body composition or performance.

A simple half-life model shows why “gone” is too strong:

That table is only an illustration based on the 12-minute figure. Individual clearance and a specific formulation can differ.

Why the growth-hormone pulse lasts longer

The molecule does not need to remain in the blood for the entire response. Once it reaches the pituitary receptor, it starts a release signal. Growth hormone can continue rising and falling after most circulating sermorelin has been cleared.

Wilton and colleagues tested this directly in 30 healthy men. Although intravenous GHRH(1-29) was rapidly eliminated, growth-hormone levels stayed elevated for about three hours (Acta Paediatrica, 1993). That study measured a hormone response, not sleep, recovery, weight, or another personal outcome. It shows why “how long is it in my blood?” and “how long does the response last?” have different answers.

The same distinction explains why a random growth-hormone blood draw can be hard to read. Growth hormone arrives in pulses, so one sample may catch a peak or a quiet stretch. A clinician may use other context and longer-lived markers when monitoring the growth-hormone pathway.

What this means for timing and accumulation

A short half-life does not create a dosing schedule on its own. The old studies used different routes, amounts, populations, and schedules, while current compounded formulations can differ in concentration. The sermorelin dosing guide explains how prescribers think through those variables without turning a study protocol into instructions.

The minute-scale blood clock also makes large day-to-day buildup of unchanged sermorelin unlikely. But the downstream hormone response can outlast the molecule, and repeated prescriptions still need monitoring. Questions about a late or missed dose belong with the prescriber and the pharmacy label, not with half-life arithmetic.

CJC-1295 with DAC runs on a different clock

CJC-1295 with DAC is often placed beside sermorelin because both signal through the GHRH receptor. DAC means drug affinity complex, a chemical handle that lets the peptide attach to albumin, a long-lived protein in the blood. That attachment changes the timing dramatically.

In two randomized studies of healthy adults, CJC-1295 with DAC had an estimated half-life of 5.8 to 8.1 days. Mean growth-hormone levels rose for at least six days, and mean IGF-1, a hormone produced in response to growth hormone, rose for 9 to 11 days (Teichman and colleagues, The Journal of Clinical Endocrinology & Metabolism, 2006). Those are trial measurements, not evidence that longer is better.

The days-long number belongs to the DAC form. It should not be copied onto CJC-1295 without DAC, including the short-acting form used in Promise's CJC-1295/ipamorelin blend. CJC-1295 without DAC explains that naming problem and the limits of the human data.

Drug testing: half-life is not a clearance deadline

For tested athletes, the rule is clearer than the detection window. The 2026 World Anti-Doping Agency Prohibited List names sermorelin under growth hormone-releasing factors and prohibits that class at all times, both in and out of competition. A prescription alone does not remove that rule.

Testing methods can also look for a breakdown product rather than only intact sermorelin. In a small method-development study, researchers detected the GHRH(3-29) breakdown product in plasma 30 minutes after one healthy volunteer received a subcutaneous dose; the 90-minute sample was negative with that method (Knoop and colleagues, Analytical and Bioanalytical Chemistry, 2016). One person and two time points cannot establish a safe detection window. Laboratories, sample types, and test sensitivity change.

A routine workplace panel is not the same as an anti-doping test. Anyone covered by sports rules needs an answer from the relevant testing authority, including whether a therapeutic use exemption is required. The 11-to-12-minute figure cannot answer that question.

Where FDA status sits

No FDA-approved sermorelin product is currently marketed — Geref was approved in 1997 and withdrawn in 2009 — and the compounded formulation offered here is not FDA-approved. The FDA's 2013 Federal Register record says the withdrawal became effective June 18, 2009, after the manufacturer discontinued Geref. The agency later determined that the products were not withdrawn for safety or effectiveness reasons.

A licensed provider may still prescribe a compounded formulation when appropriate; that decision is between the patient and the doctor. At Promise, a licensed provider reviews every request and prescribes only when sermorelin is medically appropriate; not everyone qualifies.

The useful questions to bring to a provider

Half-life answers a narrow question about blood levels. A clinical plan still needs to identify the exact formulation, why it is being considered, what will be monitored, and how its timing fits the person's health and sleep pattern. The current sermorelin product page shows the prescribed injectable option; the reviewing provider and pharmacy label set the actual plan.